• LAST PRICE
    2.6500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.7200/ 6
  • Ask / Lots
    3.1500/ 18
  • Open / Previous Close
    2.6900 / 2.6500
  • Day Range
    Low 2.6500
    High 2.7300
  • 52 Week Range
    Low 1.1500
    High 5.9899
  • Volume
    11,956
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.65
TimeVolumeDBVT
09:32 ET2612.69
09:38 ET6902.65
10:01 ET1002.66
10:21 ET2002.66
11:00 ET4002.6618
11:08 ET30002.668
11:11 ET1002.66
12:09 ET2502.72
12:14 ET1002.72
12:38 ET2002.66
01:35 ET21002.66
01:44 ET9002.6668
03:02 ET2002.68
03:16 ET5002.68
03:59 ET6352.65
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDBVT
Dbv Technologies SA
493.0M
-4.0x
---
United StatesCPLFY
Cipla Ltd
10.6B
0.0x
---
United StatesCRMD
CorMedix Inc
132.2M
-5.8x
---
United StatesASMB
Assembly Biosciences Inc
104.6M
-0.8x
---
United StatesNHWK
NightHawk Biosciences Inc
69.5M
-1.7x
---
United StatesNOVN
Novan Inc
55.7M
-1.6x
---
As of 2022-08-16

Company Information

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Contact Information

Headquarters
177-181 avenue Pierre BrossoletteMONTROUGE, France 92120
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Michel De Rosen
Chief Executive Officer, Director
Daniel Tasse
Chief of Staff
Sebastien Robitaille
Chief Medical Officer
Pharis Mohideen
Chief Legal Officer
Michele Robertson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$493.0M
Revenue (TTM)
$8.3M
Shares Outstanding
188.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.47
EPS
$-0.67
Book Value
$0.90
P/E Ratio
-4.0x
Price/Sales (TTM)
59.2
Price/Cash Flow (TTM)
---
Operating Margin
-941.64%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.